Company ProfilePremium

India Glycols Limited

Company Profile Analysis

Ticker: INDIAGLYCO.NS

ESOMAR 23 Corporate BadgeISO Certifications Badge
India Glycols Limited - Company showcase

Year Founded & Workforce

1983

1,357 Employees

India Glycols Limited logo

India Glycols Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

India Glycols Limited Overview

India Glycols is a promoter-controlled Indian industrial and consumer conglomerate built around one core competence: converting agricultural feedstock (molasses and grain) into ethanol and then into higher-value outputs. Founded in 1983 and the first company globally to make ethylene oxide (EO) and mono-ethylene glycol (MEG) from renewable molasses-based ethanol (commercial since 1989), it historically ran four segments — Bio-based Specialities and Performance Chemicals (BSPC), Potable Spirits, Bio-Fuel and Ennature Biopharma — from three integrated sites at Kashipur, Gorakhpur and Dehradun. In FY26 it generated ₹9,827 Cr gross revenue, ₹4,211 Cr net revenue, ₹654 Cr EBITDA (15.5% margin) and ₹293 Cr PAT. Its "3x3" model (three ethanol sources feeding three outputs) is the strategic glue. As of 1 September 2026 the group has been split into three listed-or-to-be-listed pure plays: a green-chemicals company (IGL), an alcohol-beverage-plus-ethanol platform (IGL Spirits) and a plant-based API/nutraceutical company (Ennature Bio Pharma).


What the company does

Pre-demerger, IGL operated an integrated agro-to-ethanol-to-derivatives value chain. Molasses (purchased from sugar mills) and grain (rice, including Food Corporation of India allocations, and other cereals) are fermented and distilled into ethanol at Kashipur (Uttarakhand) and Gorakhpur (Uttar Pradesh). That ethanol — supplemented by domestically purchased and imported ethanol when economics favour it — is routed into three outlets:

  1. Chemicals (BSPC): dehydration to bio-ethylene, oxidation to bio-EO, and conversion into bio-MEG/DEG/TEG, glycol ethers and acetates ("green solvents"), performance chemicals (oilfield chemicals, plasticisers, bio-based amines) and, historically, ethoxylates. Bio-EO derivatives (ethoxylates) were transferred to the Clariant IGL Specialty Chemicals JV in 2021, to which IGL now supplies EO under a long-term agreement. Industrial gases (oxygen, nitrogen, argon, CO₂) are produced from an air separation unit and the EO process CO₂ stream. Guar-based biopolymers (hydrocolloids) were also reported here.

  2. Potable Spirits: Extra Neutral Alcohol (ENA) is bottled into branded country liquor (CL, also "IMIL") and Indian Made Foreign Liquor (IMFL), primarily for Uttar Pradesh and Uttarakhand; IGL also bottles for Bacardi under a 15-year relationship and markets Amrut brands in select North Indian markets.

  3. Bio-Fuel: fuel-grade ethanol sold to Indian oil marketing companies (OMCs) under the national Ethanol Blended Petrol programme, plus distillers' grains (DDGS/DWGS) by-products. Reported as a separate segment from Q1 FY25 (previously within BSPC).

A fourth, smaller engine — Ennature Biopharma (Dehradun) — extracts plant-based APIs (global leader in thiocolchicoside, a muscle relaxant derived from Gloriosa seeds), natural nicotine and nicotine salts, and nutraceutical ingredients using supercritical CO₂ extraction.

Company's own description (paraphrased from FY26 investor materials)

IGL describes itself as one of India's leading manufacturers across BSPC, Bio-Fuel, Potable Spirits and Ennature Biopharma; the first company in the world to produce EO/MEG via the renewable molasses route (since 1989); exporting to more than 40 countries; offering 100+ green products from three integrated facilities spread over ~360 acres; with "green" positioned as core to its identity rather than a credential (Q4 FY26 Investor Presentation, May 2026). Management additionally claims, together with the Clariant JV, to be the world's largest supplier of bio-based speciality chemicals and the only at-scale producer of bio-based EO, glycols and glycol ethers (Q1 FY27 call, Aug 2026).

Business and revenue model

DimensionCharacterisation
Revenue modelOverwhelmingly product sales (manufacturing). Minor service income from job-work/bottling (Bacardi), power sales from Gorakhpur cogeneration, ENA sales; royalty-paying (not royalty-earning) brand arrangement with Amrut. No meaningful subscription or licensing revenue.
Gross vs net revenueGross revenue includes state excise duty on potable spirits, which inflates the top line ~2.3x. FY26 gross ₹9,827 Cr vs net ₹4,211 Cr (Q4 FY26 presentation). Analysis should use net revenue.
Value-chain positionVertically integrated from fermentation through to branded consumer goods (spirits) and intermediate/speciality chemicals (B2B). Upstream feedstock (molasses, grain) is bought; IGL does not grow cane, having exited sugar via the sale of Shakumbari Sugar and Allied Industries in 2023.
Customer typesB2B: global and Indian chemical, personal care, oil & gas, textile, automotive, packaging and pharma companies; OMCs (ethanol); the Clariant JV (EO offtake); Bacardi (bottling). B2C/B2G: state excise-regulated liquor distribution in UP/Uttarakhand/Delhi, Canteen Stores Department (CSD) and paramilitary canteens.
End-marketsPersonal care, home care/detergents, oil & gas and refineries, automotive (coolants, brake fluids), textiles (MEG, glycol ethers), paints and coatings, agrochemicals, pharma/healthcare, food & beverage, packaging (PET via MEG), mining, metal working, pulp & paper, wastewater, alcoholic beverages, transport fuel.

Independent characterisation

IGL is best understood as an ethanol arbitrage platform with three monetisation channels of very different quality. Potable spirits is the profit engine (FY26: 32% of net revenue, 52% of segment EBIT per the company's FY26 segment-share slide), protected by state licensing and by dominance in branded country liquor in UP/Uttarakhand. Bio-Fuel is a low-margin, policy-dependent volume outlet (FY26 EBIT margin 7.8%) that keeps distilleries loaded. Chemicals is a structurally challenged commodity business (bio-MEG competes against fossil MEG produced by Reliance and Middle Eastern exporters) that management is trying to pivot toward higher-margin "New Speciality" products (bio-amines, carbon-smart ethoxylates/glycols, green solvents). Historically the market applied a conglomerate discount; the demerger is explicitly designed to remove it. The key analytical tension is that the chemicals stub left in the listed IGL is the lowest-margin and least predictable piece, while the most valuable piece (spirits) now trades separately once IGL Spirits lists.

Strategy

Stated strategic themes (paraphrased from FY26 and Q1 FY27 materials)

Value unlocking via demerger: separate consumer (spirits) from B2B technology (chemicals) and life sciences, to attract dedicated investors, allow independent capital allocation, ring-fence risk and reduce the conglomerate discount.

Premiumisation in spirits: move up from country liquor to IMFL, Prestige & Above, and single malts via the Amrut partnership; focus on white spirits.

Specialty pivot in chemicals: shift from commodity glycols to performance chemicals, green solvents, bio-amines and carbon-smart products; "partner of choice" model with BASF, L'Oréal, Unilever and Mibelle (named by the CEO with permission).

3x3 feedstock flexibility: three ethanol sources (in-house, domestic purchase, import) feeding three outputs (fuel, chemicals, potable).

Deleveraging: FY26 preferential issue; IGL Spirits targeting debt-free status from FY28.

Innovation and sustainability: DSIR-approved R&D, LanzaTech C-smart collaboration, carbon-utilisation technologies (undisclosed).

Initiatives in the last 24 months

InitiativeDateDetail
Three-way demergerBoard May 2025; NCLT 17 Jul 2026; effective 1 Sep 2026Modified scheme after withdrawing KHL amalgamation
Share split 1:2Record date 12 Aug 2025Liquidity/affordability
Preferential equity issueAllotted 24 Nov 2025₹467 Cr for debt reduction and working capital
Bio-based amines commercialisationFirst sales announced Aug 2025Approvals from global majors; L'Oréal anchor (per Arihant)
Amrut brand partnershipFY26Five Amrut brands in select North Indian markets
Single malt launch for North IndiaFY26Fusion Single Malt
CSD entryFY26"Strong entry" reported; 3 brands approved, 1 pending
New state launchesPlanned FY27Andhra Pradesh, Daman & Diu
Nicotine capacityQ1 FY27Crude processing started at Kashipur
Ennature pipelineSep 2026One new API per year; dietary fibre entry
Leadership build-out2,026Spirits COO from ABD/Pernod; IR head

ESG commitments with targets: no quantified emissions target located. Cost programmes with targets: none publicly quantified beyond capex discipline.

Management medium-term aspirations (explicitly described by management as aspirations, not projections — Q1 FY27 call)

EntityMetricFY274–5 year aspiration
IGL SpiritsEBITDA (INR Cr)above 500above 1,000
IGL SpiritsIMFL volume~2x FY26 (3.4 mn cases)Top-5 Indian alco-bev ambition
IGL SpiritsLeverage—Debt-free from FY28
India Glycols (chemicals)Revenue (INR Cr)—~2,500
India Glycols (chemicals)EBITDA (INR Cr)—~400
New Speciality UnitRevenue (INR Cr)150+600–700; gross margin ~30% by ~2031–32
India Glycols (chemicals)Capex (INR Cr)5–20Modular; no large plant for ~2 years
Ennature Bio PharmaEBITDA (INR Cr)—130–150

Note: Investywise attributed the FY28 debt-free goal to IGL as a whole; the transcript attributes it to the IGL Spirits outlook. The ₹500 Cr FY27 EBITDA figure refers to IGL Spirits (₹120 Cr delivered in Q1).

Products & Services

Chemicals (BSPC; now India Glycols Ltd)

Product lineDescription / specificationTarget customersNotes
Bio-MEG (mono-ethylene glycol)Ethylene glycol from bio-ethanol via bio-ethylene and bio-EO; IGL claims to be the only maker globally of bio-MEG, DEG and TEG from bio-ethanolPET/polyester, textiles, coolants, packaging brands seeking bio-contentCommercial since 1989; repeated expansions 1995–2008; US-based Scientific Design technology partner for bio-glycols
Bio-DEG / Bio-TEGCo-products of MEG plantUnsaturated polyester resins, gas dehydration, plasticisersQ1 FY27 glycols value +83% YoY
Bio-EO and high-purity EOEthylene oxide from bio-ethanolClariant IGL JV (long-term supply); internal derivativesQ1 FY27: EO competitiveness vs Reliance improved due to crude spike
Glycol ethers and acetates ("green solvents")Ethylene glycol monoethyl ether and acetates; IGL claims to be India's largest and only bio-glycol ether maker and only Indian producer using Sulzer Chemtech continuous technologyPaints & coatings, inks, crop protection, pharma, personal care, foodQ1 FY27 volumes +6%, value +13%, gross margins close to 50% (management)
Performance chemicals / New Speciality Unit (NSU)Oilfield chemicals, plasticisers, rheology modifiers, metal-working and I&I cleaning chemicalsOil & gas, refineries, automotive, metalworkingNSU Phase-I commissioned 2023; ~₹50–60 Cr invested in new plant; FY27 aspiration ₹150 Cr+ revenue; Q1 FY27 growth +40%
Bio-based aminesDescribed as world's first bio-based amines with approvals from global majorsPersonal care (L'Oréal reported as anchor customer by Arihant)First commercial sales announced Aug 2025 (Q1 FY26 presentation)
Carbon-Smart (C-smart) ethoxylates and glycolsDerived from ethanol produced from industrial emissions (LanzaTech technology)Sustainability-led consumer brandsManagement says IGL was the first company globally to supply these; volumes small
Industrial gasesLiquid oxygen, nitrogen, argon; industrial-grade CO₂Steel, healthcare, food & beverageGlobal partnerships with Air Liquide and Praxair (technology); Q1 FY27 revenue ₹13 Cr at 23.1% EBITDA margin
Future pipelineBio-esters, speciality bio-amines, polygalactomannan derivatives, carbon-utilisation products—Management declines to quantify "transformational" carbon technologies

Pricing model: spot and contract pricing; not publicly disclosed.

Biopolymers (formerly BSPC; now Ennature Bio Pharma Ltd)

Product lineDescriptionTarget customersNotes
Guar gum and derivativesHydroxypropyl guar and PO-derivatised guar; IGL claims to be the only company globally with all types of standard and high-quality derived biopolymers (hydrocolloids)Oil & gas fracturing, textiles printing, food, personal careGuar gum plant since 2001; expansion 2015

Potable Spirits (now IGL Spirits Ltd)

Brand / offeringCategoryDetail (as disclosed)
Bunty BubblyCountry liquor (branded CL)14 million cases sold in FY25; described by IGL as the highest-selling brand in India; Asia Book of Records and Limca Book of Records recognition
Amazing Vodka (Plain, Green Apple, Orange, imported flavours)IMFL – flavoured vodkaCompetes in a ~7 million case segment; gold medal at Spirits Selection
Zumba Lemon VodkaIMFL – flavoured vodkaDouble-digit share claimed in UP, Uttarakhand, Delhi, Chandigarh, paramilitary and CSD
Soulmate Blu / Soulmate GinIMFLDescribed as a millionaire-case brand
Amazing Whisky DeluxeIMFL – deluxe whiskyLaunched into a ~36 million case segment
Single Reserve WhiskyIMFL – whiskyListed in FY26 portfolio
V2O Orange VodkaIMFL – vodkaListed in FY26 portfolio
MaQintosh Whisky (Special Edition)IMFL – Amrut partnershipAmrut legacy Karnataka brand acquired by IGL with new packaging; volume builder
MaQintosh White Label WhiskyIMFL – Amrut partnershipLaunched by IGL for the semi-premium "belly" of the market (~12 million case segment)
Prestige Green Classic WhiskyIMFL – Amrut partnershipBottled at Kashipur and Gorakhpur; IGL keeps manufacturing/marketing profit after a per-case royalty (~2.8 million case segment)
Fusion Single MaltLuxury – Amrut flagshipAmrut flagship sold in 53 countries; IGL invests, distributes and markets in select North Indian markets; target 10,000+ cases
AmalgamPremium blended malt – AmrutSame distribution model
Bacardi brands (Carta Blanca, Limon, Breezer)Contract bottling and supply chain15-year partnership; IGL Kashipur supplies North and East India; IGL says it is the only Indian partner with an exclusive Bacardi spirit-maturation facility
ENA (molasses and grain)Bulk spiritCaptive plus third-party sales

Volume data: IMFL FY26 3.4 million cases; Q1 FY27 IMFL 1.4 million cases (+55%), of which Prestige & Above ~0.5 million (~2x YoY); non-IMFL (CL) 7.5 million cases (+6%) with ₹279 Cr revenue. Management expects IMFL above 30% of PS revenue in FY27 and plans deluxe whisky, rum and semi-premium vodka launches plus defence (CSD) brand approvals (three approved, one pending) (Q1 FY27 call). Pricing: state excise-regulated MRPs; not otherwise disclosed.

Bio-Fuel (now IGL Spirits Ltd)

ProductDescriptionCustomersCapacity
Fuel-grade ethanolSpecial-grade ethanol for petrol blendingIndian OMCs under the EBP programmeTotal ethanol capacities (incl. grain) 600 KLPD at Kashipur and 500 KLPD at Gorakhpur (shared with ENA/chemicals)
DDGS / DWGSDistillers' dried/wet grains (animal feed)Feed manufacturersBy-product
PowerBiomass cogeneration at GorakhpurGridMinor

Ennature Biopharma (now Ennature Bio Pharma Ltd)

Product lineDescriptionNotes
ThiocolchicosideMuscle-relaxant API from Gloriosa superba seeds; IGL claims global leadershipQ1 FY27 sales +26% QoQ on price realisation; raw-material availability volatile
Natural nicotine and nicotine saltsLiquid nicotine for NRT and related usesSales doubled QoQ in Q1 FY27 on European customer conversions; crude processing started at Kashipur
MaxicumaNano-formulated curcumin with higher bioavailabilityBranded nutraceutical
Lutein estersExtracted with patented processesPatents for lutein ester extraction cited
Phytochemicals / herbal extractsArtemisia, stevia, rosemary, marigold, sage germplasm; contract farming with buy-backSupercritical CO₂ extraction (SCFE), solvent, aqueous extraction, bio-fermentation
PipelineOne new API per year; entry into dietary fibre; niche moleculesAnnounced at 2 Sep 2026 investor meet (Sahi/Fyers reports)

Financial Narrative

All figures consolidated, ₹ Cr, from Q4 FY26 Investor Presentation (5-year trajectory and FY24–FY26 financial summary) unless marked "computed". FY22–FY23 detail below EBITDA and full balance sheets were not available in sources reviewed; cells left blank.

Income statement

Notes: Gross profit is not reported by IGL in the presentation format and is not publicly disclosed in sources reviewed. FY22 and FY23 reported PAT computed by adding back the exceptional items disclosed in the presentation footnote (₹221.34 Cr FY22; ₹28.13 Cr FY23) — the footnote does not state whether these are pre- or post-tax, so treat as approximate. EPS FY25 and FY26 are company-reported; FY22–FY24 computed as adjusted PAT ÷ 6.19 Cr split-adjusted shares. Standalone FY26: net revenue ₹4,211 Cr, EBITDA ₹690 Cr, PAT ₹282 Cr (includes ~₹39 Cr Clariant JV dividend in Q4).

Margins and growth

CAGRs (computed): net revenue FY22–FY26 10.1%; gross revenue FY22–FY26 10.5%; EBITDA FY22–FY26 23.9%; adjusted PAT FY22–FY26 25.3%. Company-stated FY24–FY26 CAGRs: net revenue 13.1%, EBITDA 23.6%, PAT 30.1%.

Commentary. The defining trend is five consecutive years of EBITDA margin expansion (9.6% to 15.5%), which management attributes to feedstock management, cost control, mix improvement and new businesses (Q1 FY27 call). The FY23 revenue dip reflects the transfer of the bio-EO derivatives business to the Clariant JV (deconsolidated from mid-2021) and weak glycol pricing. The FY24 inflection came from grain-based distilleries (commissioned 2022) which simultaneously enabled the Bio-Fuel business and cushioned ENA costs for spirits and chemicals. Below EBITDA, the story is less clean: depreciation rose 53% FY24–FY26 as new capacity came on stream, and finance costs stayed near ₹165 Cr in FY25–FY26, holding interest coverage below 3x. The JV contribution (₹46 Cr in each of FY25 and FY26) is a meaningful 12% of FY26 PBT.

Balance sheet

Goodwill and intangibles: not separately disclosed in the presentation format; not publicly disclosed in sources reviewed. Current assets computed as receivables + cash + inventory + other current assets; current liabilities as payables + short-term borrowings + other current liabilities.

Commentary. The balance sheet expanded ₹906 Cr in two years, driven by ₹1,274 Cr of fixed-asset growth (distilleries, NSU). FY25 marked peak leverage (net debt ₹1,727 Cr). The November 2025 preferential issue (₹467 Cr) plus a sharp ₹280 Cr inventory release in FY26 cut net debt by ~₹200 Cr and lifted equity to ₹2,933 Cr. However, the mix shifted toward short-term borrowings (₹919 Cr), which partly explains the persistently negative working-capital position. The Financial Express (via Askfuzz) reported that ~₹804 Cr of debt was prepaid in a single quarter after the issue — this figure was not reconciled with the year-end balance and should be treated as gross repayment rather than net reduction.

Cash flow

Note: the presentation labels the cash-flow table "₹ Mn" while the slide header states "Figures in ₹ Cr"; the magnitudes are consistent with ₹ Cr. Capex is not separately reported; investing cash flow is used as a capex proxy and includes investments. Dividends paid and buybacks are not separately disclosed in sources reviewed; IGL has not announced any buyback.

Commentary. FY26 operating cash flow more than doubled (+112%) to ₹769 Cr — management's headline cash metric — largely on working-capital release. Free cash flow was roughly break-even in FY26 after two years of heavy negative FCF, meaning deleveraging was funded by equity, not internal accruals. Management now guides to minimal chemicals capex (₹5–20 Cr in FY27), which, if sustained, should turn FCF clearly positive.

Ratios

First four rows company-reported; remaining rows computed (FY24 ROE/ROA/asset turnover use year-end values because FY23 balance sheet was unavailable). ROIC: not publicly disclosed; ROCE is the closest company metric.

Commentary. Returns are improving but remain modest for the risk profile: ROCE of 11.9% is likely below a reasonable pre-tax cost of capital for a mid-cap with A- credit. Leverage improved meaningfully in FY26 but a current ratio of 0.66 signals a working-capital structure dependent on rolling short-term bank lines — a point CARE has flagged in its rating sensitivities around liquidity buffers.

Latest quarter: Q1 FY27 (quarter ended 30 June 2026)

Sources: Multibagg, ScanX, Investywise reports of the 12 Aug 2026 results; Q1 FY27 call. Q1 FY26 EBITDA computed from reported growth (170/1.125); the CFO cited Q1 FY26 margin as 14.3% on the call while Multibagg reports 14.5% — minor discrepancy. Board approved results on 12 Aug 2026 after limited review.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsPost-demerger home

Bio-based Specialities & Performance Chemicals (BSPC)

Bio-glycols (MEG/DEG/TEG), glycol ethers & acetates (green solvents), bio-EO sales (incl. to JV), performance chemicals (oilfield, plasticisers, bio-amines), biopolymers/guar derivatives, industrial gases, ENA (per segment description)

Chemicals + gases stay in India Glycols Ltd; biopolymers move to Ennature Bio Pharma Ltd

Potable Spirits (PS)

Branded country liquor (UP, Uttarakhand), IMFL, Bacardi bottling, ENA

IGL Spirits Ltd

Bio-Fuel (BF)

Fuel ethanol to OMCs, DDGS/DWGS

IGL Spirits Ltd

Ennature Biopharma (EB)

Plant-based APIs (thiocolchicoside), natural nicotine & salts, nutraceuticals, phytochemicals

Ennature Bio Pharma Ltd

Potable Spirits

Uttar Pradesh, Uttarakhand (market leadership in branded CL), Delhi, Himachal Pradesh, Chandigarh; CSD/paramilitary nationwide

Planned launches in Andhra Pradesh and Daman & Diu (Q4 FY26); East India targeted for Amrut brands; Delhi growth dilutes margin vs Uttarakhand (Q1 FY27 call)

Bio-Fuel

Domestic OMCs

Industry excess capacity; government considering higher blending (Q4 FY26)

BSPC

India plus exports (Middle East, US, Europe)

Middle East oil & gas chemical exports collapsed and westbound freight rose 5–20x amid the 2026 regional conflict (Q1 FY27 call)

Ennature

Global API and nicotine customers (Europe cited)

Nicotine conversions in Europe driving growth

Segment net revenue (INR Cr)

Segment net revenue (INR Cr)FY24FY25FY26

BSPC net revenue (INR Cr)

—1,3421,203

Potable Spirits net revenue (INR Cr)

—1,1631,331

Bio-Fuel net revenue (INR Cr)

—1,0441,470

Ennature Biopharma net revenue (INR Cr)

—219208

Total net revenue (INR Cr)

3,2943,7684,211

Segment EBIT (INR Cr)

Segment EBIT (INR Cr)FY25FY26

BSPC EBIT (INR Cr)

125141

Potable Spirits EBIT (INR Cr)

256285

Bio-Fuel EBIT (INR Cr)

57115

Ennature Biopharma EBIT (INR Cr)

217

Segment EBIT margin (%)

Segment EBIT margin (%)FY24FY25FY26

BSPC EBIT margin (%)

—9.311.7

Potable Spirits EBIT margin (%)

—22.021.4

Bio-Fuel EBIT margin (%)

—5.47.8

Ennature Biopharma EBIT margin (%)

—9.53.5

Segment metric FY26

BSPC

Potable Spirits

Bio-Fuel

Net revenue YoY growth (%)

-10.414.440.9

EBIT YoY growth (%)

12.511.1103.3

Share of net revenue (%)

293235

Share of segment EBIT (%)

265221

Segment net revenue (INR Cr) (Quarterly)

Segment net revenue (INR Cr)Q4FY25Q1FY26Q2FY26Q3FY26Q4FY26Q1FY27

BSPC (INR Cr)

254300288313301363

Potable Spirits net (INR Cr)

284342338345306361

Bio-Fuel (INR Cr)

273348423394305323

Ennature Biopharma (INR Cr)

525143506383

Segment Revenue

Pro-forma entityBusinessesFY26 net revenue (INR Cr)FY26 share (%)Q1FY27 net revenue (INR Cr)Q1FY27 EBITDA (INR Cr)Q1FY27 EBITDA margin (%)

India Glycols Ltd (listed)

Glycols, bio-glycols, glycol ethers, new speciality products, industrial gases

1,163283454011.6

IGL Spirits Ltd (to be listed)

IMFL, country liquor, ENA, Bio-Fuel

2,8016769412017.3

Ennature Bio Pharma Ltd (to be listed)

Plant APIs, nicotine, nutraceuticals, bio-polymers

2476901011.1

Consolidated (pre-demerger)

All

4,2111001,13017015.0

Income Statement and Per-Share Data

Metric (INR Cr unless stated)FY2022FY2023FY2024FY2025FY2026

Gross revenue from operations (INR Cr)

6,6016,6427,9229,0399,827

Net revenue, net of excise (INR Cr)

2,8682,6513,2943,7684,211

Other income (INR Cr)

——26155

EBITDA (INR Cr)

277319428525654

Depreciation (INR Cr)

——101115155

EBIT (INR Cr)

——327410499

Finance cost (INR Cr)

——121164167

Share of JV profit (INR Cr)

——174646

Profit before tax (INR Cr)

——223292377

Tax (INR Cr)

——506184

Adjusted PAT, excl. exceptionals (INR Cr)

119113173231293

Reported PAT incl. exceptionals, computed (INR Cr)

340141173231293

Basic EPS, split-adjusted (INR)

19.218.327.937.346.0

Dividend per share, split-adjusted (INR)

————7.5

Margin Analysis (%)

Metric (%)FY2022FY2023FY2024FY2025FY2026

EBITDA margin on net revenue (%)

9.611.912.913.915.5

EBIT margin on net revenue, computed (%)

——9.910.911.8

Adjusted PAT margin (%)

4.14.35.26.16.9

Net revenue YoY growth, computed (%)

—-7.624.314.411.8

Gross revenue YoY growth, computed (%)

—0.619.314.18.7

Balance Sheet

Balance sheet item (INR Cr)FY2024FY2025FY2026

Fixed assets (INR Cr)

3,1713,7364,445

Capital work in progress (INR Cr)

849837

Investments incl. JV (INR Cr)

335381389

Trade receivables (INR Cr)

384365351

Inventory (INR Cr)

1,1061,171891

Cash and bank balance (INR Cr)

1387750

Total assets (INR Cr)

5,6176,1766,523

Shareholders' funds (INR Cr)

2,0512,2562,933

Long-term borrowings (INR Cr)

7251,040659

Short-term borrowings (INR Cr)

596764919

Total debt, computed (INR Cr)

1,3211,8041,578

Net debt, computed (INR Cr)

1,1831,7271,528

Trade payables (INR Cr)

1,099979788

Working capital, current assets minus current liabilities, computed (INR Cr)

-430-505-776

Cash flow item (INR Cr)

Cash flow item (INR Cr)FY2024FY2025FY2026

Cash flow from operations (INR Cr)

439362769

Cash flow from investing (INR Cr)

-503-736-767

Cash flow from financing (INR Cr)

9035423

Free cash flow proxy, CFO plus CFI, computed (INR Cr)

-64-3742

Financial Ratios (x) and Returns & Leverage Ratios (%)

RatioFY2022FY2023FY2024FY2025FY2026

Debt to equity (x)

0.590.680.640.800.54

Interest coverage, EBIT/finance cost (x)

2.822.262.712.502.98

ROCE (%)

7.57.710.511.611.9

Cash conversion cycle (days)

6059436445

ROE on average equity, computed (%)

——8.410.711.3

ROA on average assets, computed (%)

——3.13.94.6

Current ratio, computed (x)

——0.820.780.66

Net debt to EBITDA, computed (x)

——2.763.292.34

Asset turnover, net revenue/average assets, computed (x)

——0.590.640.66

Income Statement and Margin Analysis (%)

Metric (INR Cr unless stated)Q1FY26Q1FY27YoY change (%)

Gross revenue from operations

2,503.12,988.419.4

Net revenue

1,0401,1308.6

EBITDA

15117012.5

EBITDA margin (%)

14.515.0—

Finance cost

4525-44.4

Share of JV profit

18.620.610.8

PBT

—102.6—

PAT (consolidated)

73.396.832.2

PAT (standalone)

—76.644.9

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Share Price History

DatePrice (INR)BasisSource

30 May 2025

1,885.00

Pre-split, FV ₹10

Angel One

17 Nov 2025

1,134.60

Post-split intraday record high

Business Standard

31 Mar 2026

~849

Implied: ₹5,690.24 Cr ÷ 6.70 Cr shares (computed)

Q4 FY26 presentation

10 Aug 2026

1,125.00

Post-split, cum-demerger

Upstox

1 Sep 2026

1,112.90

Last cum-demerger close

Askfuzz/Business Today

2 Sep 2026

229.85 open; 236.20 close

Ex-demerger, chemicals-only

Askfuzz; Fyers

17 Sep 2026

266.95

Ex-demerger

Anand Rathi

Valuation Snapshot

MultipleValueBasis / caveat

P/E (pre-demerger)

~22x

~₹6,600 Cr valuation on trailing earnings around NCLT approval (Financial Express via Askfuzz, Jul 2026)

EV/EBITDA (pre-demerger)

~13x

Same source

EV/Sales (pre-demerger, computed)

~1.9x

(₹6,600 Cr + FY26 net debt ₹1,528 Cr) ÷ FY26 net revenue ₹4,211 Cr

P/B (pre-demerger, computed at 31 Mar 2026)

~1.9x

₹5,690 Cr ÷ equity ₹2,933 Cr

P/E (post-demerger, aggregator)

21.29x

Anand Rathi, 17 Sep 2026 — basis unclear (likely mixes pre-demerger EPS); not reliable

P/B (post-demerger, aggregator)

2.01x

Same caveat

Peer: Radico Khaitan

Share price ~₹4,348 (31 Jul 2026); FY26 PAT ₹605 Cr

—

Analyst Ratings & Targets

BrokerNoteView

Arihant Capital

Q3 FY26 and Q4 FY26 result updates

SOTP-based target implying ~41.6% upside (Q4 FY26 note); exact target price not captured

InCred Equities

Hosted Q1 FY27 call

Rating not disclosed

Capital Markets

ItemDetail

Dividend FY26

Interim ₹7.50 per ₹5 share

Buybacks

None announced

Credit rating

CARE A- (RWD) LT ₹1,229.79 Cr; CARE A- / A2+ (RWD) LT/ST ₹450 Cr; CARE A2+ (RWD) ST ₹850 Cr (6 Mar 2026). History: CARE A; Stable/A1 until 5 Mar 2024 downgrade. Moody's/S&P/Fitch: not rated

Debt maturity

Not publicly disclosed in sources reviewed; FY26: long-term borrowings ₹659 Cr, short-term ₹919 Cr; allocation across the three entities post-demerger not yet disclosed

Capital structure metric

FY2024

Shares outstanding, split-adjusted (Cr)

6.19

Analyst Conclusions

Management guidance and consensus

Management has deliberately framed its targets as aspirations: IGL Spirits EBITDA above ₹500 Cr in FY27 (₹120 Cr achieved in Q1, i.e., a run-rate of ~₹480 Cr requiring acceleration) and above ₹1,000 Cr in four to five years with debt-free status from FY28; chemicals (continuing IGL) revenue of ~₹2,500 Cr and EBITDA of ~₹400 Cr in four to five years (versus FY26 pro-forma net revenue of ₹1,163 Cr); Ennature EBITDA of ₹130–150 Cr (versus Q1 FY27 annualised ~₹40 Cr). No formal sell-side consensus is available.

Bull case

  1. Sum-of-the-parts re-rating: once IGL Spirits lists, a spirits-plus-ethanol platform with FY26 net revenue ₹2,801 Cr and Q1 FY27 EBITDA margin 17.3% could command alco-bev multiples well above the blended ~13x EV/EBITDA the group traded at pre-demerger.

  2. Margin trajectory is structural: five straight years of EBITDA margin expansion (9.6% to 15.5%), finance costs nearly halved in a year, and capex now minimal suggest earnings can compound faster than revenue.

  3. Optionality in green chemistry: a unique bio-EO/glycol platform, bio-amines with L'Oréal, and carbon-smart products give the continuing IGL a credible specialty story if NSU scales toward ₹600–700 Cr.

Bear case

  1. The stub is the weakest piece: continuing IGL (chemicals and gases) earned only ~11.6% EBITDA margin in Q1 FY27 and its FY26 revenue fell; its competitiveness depends on elevated crude prices that may not persist.

  2. Execution and allocation risk: listings of IGL Spirits and Ennature are still pending; debt allocation is undisclosed; CARE keeps ratings on watch. Shared-site operations at Kashipur create related-party complexity.

  3. Aspirations look stretched: chemicals revenue must roughly double and Ennature EBITDA must rise ~3–4x; FY26 FCF was only ~break-even and the deleveraging relied on dilution.

Catalysts and monitorables (next 12 months)

Catalyst / monitorableExpected timingWhy it matters
Listing and price discovery of IGL Spirits and Ennature Bio PharmaQ3–Q4 FY27 (company indicated 1–3 months from record date per Askfuzz)Determines SOTP value realisation
Disclosure of debt and asset allocation across three entitiesWith Q2 FY27 results (Nov 2026)Credit rating resolution
CARE rating resolutionPost-allocationFunding costs
Q2 FY27 results (first post-demerger quarter for IGL standalone)Nov 2026Baseline for chemicals stub
IMFL volume run-rate vs doubling aspiration; new launches (deluxe whisky, semi-premium vodka), AP and Daman & Diu entryThrough FY27IGL Spirits ₹500 Cr EBITDA test
Crude oil and EO/MEG spreadsContinuousChemicals competitiveness
Ethanol blending policy beyond E20; OMC procurement pricesFY27Bio-Fuel margins
Customs second appeal on ₹33.43 Cr demandOpenContingent liability
Clariant JV milestone payments and dividendsQ4 FY27Cash to IGL
Index inclusion of new entitiesOn listingFlows

Analyst verdict

India Glycols has done what many Indian mid-cap conglomerates promise and few deliver: it has repaired its margins, cut leverage and broken itself up. The FY22–FY26 record is genuinely good — net revenue compounded ~10%, EBITDA ~24% and adjusted PAT ~25%, with EBITDA margin up nearly six points — and Q1 FY27 extended the run with record EBITDA of ₹170 Cr and PAT up 32%. The demerger, effective 1 September 2026, is the right answer to a persistent conglomerate discount, because the businesses have nothing in common except ethanol: a state-licensed consumer franchise, a policy-priced fuel business, a commodity-exposed chemicals platform and a niche botanical API maker.

The analytical consequence, however, is that "India Glycols" is now a different and smaller company. The continuing listed entity holds the chemicals and gases businesses — roughly 28% of FY26 net revenue, with low-teens EBITDA margins, recent revenue decline and a competitive position that improved in 2026 largely because of an exogenous crude spike. Its long-term aspiration (₹2,500 Cr revenue, ₹400 Cr EBITDA) is credible only if the New Speciality Unit and bio-amines scale with customers like L'Oréal and BASF; there is not yet enough disclosure to underwrite that.

The more compelling equity is likely to be IGL Spirits once listed: captive ENA, a dominant branded country-liquor franchise in two large states, accelerating IMFL volumes and Amrut-led premiumisation, with an explicit ₹500 Cr+ FY27 EBITDA aspiration. Ennature is an interesting option on a recovering nicotine and API business but is small.

Net verdict: constructive on the group's value-unlocking path, neutral-to-cautious on the continuing chemicals stub in isolation until (i) debt allocation and the CARE rating are resolved, (ii) Q2–Q3 FY27 confirm chemicals margins hold as crude normalises, and (iii) the two new entities list and trade. Investors should evaluate the three entities on a combined basis for at least the next two quarters.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleBackground / tenureCompensation

Uma Shankar (U.S.) Bhartia

Chairman & Managing Director; promoter

Re-appointed CMD for 5 years from 1 Apr 2021 (Feb 2021 filing) and again re-appointed by the Board on 16 May 2025; chairs the Clariant IGL JV; Kashipur Holdings group

—

Rupark Sarswat

Chief Executive Officer

CEO tenure ~4.4 years (Simply Wall St)

₹36.2 million total (Simply Wall St; breakdown not disclosed)

Anand Singhal

Chief Financial Officer

——

Ankur Jain

Head (Legal) & Company Secretary; Compliance Officer

——

Manoj Kumar Rai

Executive Director & COO, IGL Spirits Ltd (Spirits and Ethanol)

27 years' experience; B.Tech IIT Delhi, PGDM IIM Lucknow; former Chief Revenue Officer at Allied Blenders and Distillers; 19 years at Pernod Ricard India; earlier Marico, Saregama

—

Akshay Bansal

Executive Director, Ennature Bio Pharma Ltd

——

S.K. Shukla

Head, Liquor Business

——

Gagan Kwatra

Head of Investor Relations (joined 2026)

~15 years in IR/consulting incl. Jubilant FoodWorks, LT Foods, KPMG

—

“—” = not publicly disclosed.

Board of Directors

NameCategoryNotes

U.S. Bhartia

Chairman & MD (Executive, Promoter)

Chairs CSR-type committee per NSE filing (chairperson since 14 Feb 2015 of the listed committee)

Jayshree Bhartia

Non-Executive, Non-Independent

Director since 28 May 1999; spouse of CMD; holds 4,58,006 shares (0.68%) per MarketScreener (Nov 2025)

Pragya Bhartia Barwale

Non-Executive, Non-Independent (from 12 Aug 2026; previously Whole-Time Director & KMP since 24 Jun 2020)

Daughter of CMD

Alok Singhal

Listed as Executive Director by data providers (Arihant/Muthoot)

—

Independent directors (per 2024–25 data-provider listings)

Pradip Kumar Khaitan, Jitender Balakrishnan, Ravi Jhunjhunwala, Jagmohan N. Kejriwal, Shukla Wassan, Ravi Kumar, Samrat Banerjee, Sushil Dutt Salwan

Some of these may have completed terms; verify against the latest Corporate Governance Report

Major Shareholders

Holder categoryStake (%)

Promoter group (incl. Kashipur Holdings Ltd 49.77%)

59.63

Foreign institutional investors

2.27

Domestic institutions

5.20

Public and others

32.90

Competitive Landscape

Competitors by Segment

SegmentCompetitorPositioning vs IGL

Glycols / EO (chemicals)

Reliance Industries

Dominant fossil MEG/EO producer in India; sets domestic EO price benchmark; IGL's bio-EO was at a cost disadvantage 2021–25 until the 2026 crude spike

Glycols (imports)

Middle East producers (e.g., SABIC and regional crackers)

Low-cost MEG exporters into India; 2026 supply disruptions helped IGL

Bio-based chemicals

Godavari Biorefineries

Closest Indian peer in ethanol-based chemicals; FY26 consolidated revenue ₹1,987.9 Cr; bio-based chemicals segment ₹578 Cr, PBIT ₹36 Cr

Speciality chemicals / solvents

Laxmi Organic Industries, Jubilant Ingrevia

—

Ethoxylates (via JV)

India Glycols' own JV with Clariant competes with other surfactant makers

—

Potable Spirits (IMFL)

Radico Khaitan

Strong in UP; FY26 net revenue ₹6,050 Cr, EBITDA ₹1,018.5 Cr (16.8%); P&A 70% of IMFL value

Potable Spirits (IMFL)

United Spirits (Diageo), Pernod Ricard India, Allied Blenders and Distillers

—

Country liquor / IMIL + bulk alcohol

Globus Spirits

FY26 standalone revenue ₹3,621 Cr (+2.7%); P&A revenue ₹164 Cr; 15.7 mn regular cases

Country liquor (UP/UK)

Associated Alcohols & Breweries, Tilaknagar (regional IMFL), other UP distillers

Regional rivals; IGL claims market leadership in branded CL in UP/UK

Bio-Fuel

Balrampur Chini, Triveni Engineering, Gulshan Polyols, Godavari Biorefineries, Globus Spirits

Ethanol suppliers to OMCs; India now has excess capacity

Ennature (APIs/nutraceuticals)

Sami-Sabinsa, Arjuna Natural, Synthite, Indena (thiocolchicoside), natural nicotine extractors

—

Peer Comparison FY2026

MetricIndia Glycols (pre-demerger)Radico KhaitanGlobus SpiritsGodavari Biorefineries

Revenue (INR Cr)

4,2116,0503,6211,988

Revenue growth YoY (%)

11.8252.76.3

EBITDA margin (%)

15.516.8——

Net income (INR Cr)

293605——

Recent Developments

--

Company Snapshot

$120.1M

Revenue

1,357

Employees

1983

Founded

Noida, India

Headquarters

SWOT Analysis

Strengths

  • Five-year margin uptrend: EBITDA margin rose every year from 9.6% (FY22) to 15.5% (FY26) (Q1 FY27 call; Q4 FY26 presentation).
  • Spirits profit engine: Potable Spirits FY26 EBIT ₹285 Cr at 21.4% margin, ~52% of segment EBIT on 32% of revenue (Q4 FY26 presentation).
  • Feedstock integration: 600 KLPD (Kashipur) and 500 KLPD (Gorakhpur) ethanol capacity enabling the 3x3 model (Q4 FY26 presentation).
  • Mass-market brand strength: Bunty Bubbly sold 14 million cases in FY25; market leadership in branded CL in UP and Uttarakhand (Q4 FY26 presentation).
  • Unique green-chemistry position: first renewable-route EO/MEG producer since 1989; claimed only at-scale bio-EO/glycol/glycol-ether producer globally (company statements).
  • Blue-chip partnerships: Clariant JV contributing ₹46 Cr share of profit in FY26; 15-year Bacardi relationship; co-development with BASF, L'Oréal, Unilever, Mibelle (Q4 FY26 presentation; Q1 FY27 call).
  • Deleveraging delivered: finance cost fell from ₹45 Cr (Q1 FY26) to ₹25 Cr (Q1 FY27); D/E from 0.80x to 0.54x (FY25–FY26).

Weaknesses

  • Modest returns: ROCE 11.9% and computed ROE 11.3% in FY26 despite record profits (Q4 FY26 presentation; computation).
  • Tight liquidity: computed current ratio 0.66x and negative working capital (₹-776 Cr) at FY26; short-term borrowings ₹919 Cr.
  • Weak FCF history: FCF proxy of ₹-374 Cr in FY25 and ~₹2 Cr in FY26; deleveraging relied on a ₹467 Cr equity issue.
  • Chemicals volatility: BSPC revenue fell 10.4% in FY26 and 21.95% YoY in Q2 FY26 (Business Standard).
  • Ennature margin collapse: FY26 EBIT ₹7 Cr (3.5% margin) vs ₹21 Cr (9.5%) in FY25.
  • Geographic concentration: spirits revenue concentrated in UP, Uttarakhand and Delhi (Q1 FY27 call).
  • Disclosure gaps: no geographic split, R&D spend or detailed segment history in investor materials reviewed; FY24 segment data on new basis unavailable.

Opportunities

  • Conglomerate-discount removal: separate listings of IGL Spirits and Ennature (pending).
  • IMFL scale-up: Q1 FY27 IMFL volume +55%; P&A ~2x; FY27 volume-doubling aspiration (Q1 FY27 call).
  • Amrut premium portfolio: Fusion single malt target 10,000+ cases in IGL's states; expansion to East India.
  • Specialty chemicals pipeline: NSU aspiration ₹600–700 Cr revenue in 4–5 years; bio-amines with L'Oréal.
  • Higher ethanol blending: government considering blending beyond E20 (Q4 FY26 presentation).
  • Nicotine and API growth: Q1 FY27 Ennature revenue +65%, EBIT ₹7.3 Cr vs ₹1.2 Cr; one-new-API-per-year plan.
  • Crude-driven competitiveness: 2026 crude spike made bio-EO cost-competitive with Reliance EO (Q1 FY27 call).

Threats

  • Excise and regulatory risk: state excise policy changes in UP/Uttarakhand/Delhi can reset pricing and volumes.
  • Ethanol overcapacity: Q4 FY26 presentation notes India now has excess ethanol capacity — pricing pressure risk.
  • Feedstock price risk: grain and molasses costs; FCI rice allocation dependence.
  • Geopolitical disruption: 2026 Middle East conflict collapsed oil & gas chemical exports to the region and raised westbound freight 5–20x (Q1 FY27 call).
  • Fossil competition reversal: if crude falls, bio-EO's newly gained cost parity vs Reliance may reverse.
  • Litigation overhang: ₹33.43 Cr customs duty demand upheld at first appeal; second appeal pending (Mar 2026 disclosure).
  • Rating uncertainty: CARE A- on Rating Watch with Developing Implications pending post-demerger debt allocation.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
16 May 2025Board approves scheme of arrangement (Ennature, IGL Spirits) and re-appoints U.S. Bhartia as CMDStart of the restructuring path
30 May 2025FY25 results; Board approves 1:2 share split; stock hits 52-week high ₹1,948.50 (pre-split)Strong annual profit growth
22 Jul 2025Shareholders approve split by postal ballotCorporate action approval
11 Aug 2025Q1 FY26 results; Bio-Fuel revenue +45.4% to ₹348 Cr; first commercial bio-amine sales announcedBio-fuel momentum; specialty milestone
12 Aug 2025Split record date (FV ₹10 to ₹5)Shares doubled to ~6.19 Cr
16 Oct 2025Board approves preferential issueDeleveraging plan
12 Nov 2025EGM approves preferential issue—
Mid-Nov 2025Q2 FY26: consolidated PAT +30.9% to ₹65.06 Cr; net revenue +13.6% to ₹1,092 Cr; Bio-Fuel revenue +62.9%; BSPC -21.95%; Ennature -28.7%Stock hits record ₹1,134.60 intraday (17 Nov 2025)
24 Nov 2025Allotment of 51,03,765 shares at ₹915 (₹467 Cr)Debt reduction; equity dilution ~8%
18 Dec 2025Customs order: ₹32.95 lakh duty plus equal penalty on Ennature imports (Jun 2020–Sep 2024 classification)Minor; appeal planned
–Q3 results: BSPC ₹313 Cr; PS net ₹345 Cr; Ennature ₹50 CrSteady; chemicals recovering
27 Feb 2026 (disclosed 13 Mar 2026)Commissioner (Appeals), Noida partially allows appeal on ₹33.43 Cr customs duty case: duty and interest upheld, penalty reduced, redemption fine waived; IGL to file second appealContingent liability reduced but not removed
6 Mar 2026CARE retains CARE A- / A2+ on Rating Watch with Developing Implications on ₹2,529.79 Cr of facilities; withdraws ₹72.63 Cr BG ratingRating outcome tied to post-demerger debt allocation
Q4 FY26Dividend income from Clariant JV (~₹39 Cr per CFO)Boosts standalone Q4 EBITDA to ₹203 Cr
9 Apr 2026NCLT procedural order on scheme (per ScanX)Scheme progress
15 Apr 2026Gujarat GST e-way bill penalty cut from ₹7.21 lakh to ₹10,000 on appeal; no further appealImmaterial
14 May 2026Q4/FY26 results: FY26 net revenue +11.8% to ₹4,211 Cr; EBITDA +24.5% to ₹654 Cr; PAT +26.8% to ₹293 CrRecord year
18 May 2026Investor presentation; NCLT hearing set for 21 May 2026—
21–22 May 2026NCLT hearing could not proceed; adjournedTimeline slip
–Interim dividend ₹7.50 per share declaredShareholder return
17 Jul 2026NCLT Allahabad sanctions the schemeKey catalyst
12 Aug 2026Q1 FY27 results: PAT +32% to ₹96.8 Cr; EBITDA record ₹170 Cr; Pragya Bhartia Barwale re-designated non-executiveStrong start; governance change
14 Aug 2026Earnings call: new spirits COO (ex-ABD, ex-Pernod) and IR head introduced; first multi-year aspirations by entityStrategy transparency improves
20 Aug 2026Q1 FY27 transcript filed—
21 Aug 2026Effective date (1 Sep) and record date (2 Sep) fixed; Ennature board constitutedExecution
25–26 Aug 2026NSE circular for special pre-open session; dummy symbols DUMMYINGL1/2 added to Nifty Total Market, Microcap 250, Smallcap 500, Sugar & Ethanol indicesIndex treatment
28 Aug 2026Analyst/investor meet scheduled for 2 Sep in Mumbai—
1 Sep 2026Demerger effective; IGL closes at ₹1,112.90 (cum-demerger)Structural break
2 Sep 2026Record date; IGL opens ex-demerger at ₹229.85 (range ₹229–241.30; VWAP ₹239.07); IGL Spirits and Ennature presentations; Ennature outlines one-API-per-year plan and dietary-fibre entryPrice reset ~79% (mechanical)
17 Sep 2026IGL closes ₹266.95 (Anand Rathi)Post-demerger price discovery
Pending (as of 7 Oct 2026)Listing approvals and trading start for IGL Spirits and Ennature Bio PharmaNot confirmed in sources reviewed

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Income Statement: Revenue & Gross Profit: Gross revenue from operations rose from INR 66,010 Mn in FY2022 to INR 98,270 Mn in FY2026.
India Glycols Limited — Income Statement: Revenue & Gross Profit
Series (INR Mn)FY2022FY2023FY2024FY2025FY2026
Gross revenue from operations66,01066,42079,22090,39098,270
Net revenue, net of excise28,68026,51032,94037,68042,110

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. India Glycols Ltd — Q4 & FY26 Investor Presentation, filed 18 May 2026 ( (nsearchives.nseindia.com)
  2. India Glycols Ltd — Q1 FY27 Earnings Conference Call Transcript, call 14 Aug 2026, filed 20 Aug 2026 ( (nsearchives.nseindia.com)
  3. India Glycols Ltd — Q1 FY27 Investor Presentation, 14 Aug 2026 ( (nsearchives.nseindia.com)
  4. India Glycols Ltd — Q1 FY26 Investor Presentation, 11 Aug 2025 (NSE archive)
  5. India Glycols Ltd — H1 FY25 Investor Presentation (BSE archive)
  6. India Glycols Ltd — IGL Spirits investor presentation, 2 Sep 2026 (NSE archive)
  7. India Glycols Ltd — Preferential allotment disclosure, 26 Nov 2025 (NSE archive)
  8. India Glycols Ltd — Credit rating update, 10 Mar 2026, with CARE press release 6 Mar 2026 (NSE archive)
  9. CARE Ratings — Press releases on India Glycols, 5 Mar 2024 and 24 Mar 2025
  10. India Glycols Ltd — Reg. 30 customs order disclosure, 13 Mar 2026; GST appeal disclosure, 15 Apr 2026; director re-designation, 12 Aug 2026 (NSE archive)
  11. India Glycols Ltd — Q2 FY22 results filing and Sep/Dec 2021 investor presentations (BSE archive)
  12. NSE Indices Ltd — Press release on corporate action adjustment, 26 Aug 2026 (niftyindices.com)
  13. Clariant — Media releases on JV with India Glycols, 11 Mar 2021 and Jul 2021 (clariant.com; CHEManager)
  14. NSE integrated governance filing (iXBRL), 29 Apr 2026
  15. Business Standard / Capital Market — Q2 FY26 results coverage, Nov 2025
  16. Business Today — Ex-demerger price coverage, 2 Sep 2026
  17. Arihant Capital — India Glycols Q3 FY26 and Q4 FY26 result updates
  18. Multibagg, ScanX, Investywise, Kalkine, Univest — Q1 FY27 results coverage, Aug 2026
  19. Sahi, Askfuzz, Indian Pharma Post, Chemindigest — demerger coverage, Jul–Sep 2026
  20. Angel One, DSIJ, Upstox, Choice India, Tradingqna — share split coverage, 2025
  21. Morningstar, Simply Wall St, MarketScreener, Arihant/Muthoot data pages, Fyers, Anand Rathi — company profile, management, price data
  22. Peers: FilingReader and StockAnalysis (Radico Khaitan FY26); IndiaInfoline (Globus Spirits FY26 Directors' Report); 5paisa/Trendlyne (Godavari Biorefineries FY26)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.